Bicara Therapeutics (BCAX) Cash from Operations (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Cash from Operations data on file, last reported at 37508000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 33.45% year-over-year to 37508000.0; the trailing twelve-month figure through Mar 2026 stood at 116236000.0 (down 31.68% YoY), and the FY2025 full-year result was 106834000.0, down 42.92% from the prior year.
• Cash from Operations for Q1 2026 stood at 37508000.0, down from 23886000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 8036000.0 in Q4 2023 and bottomed at 37508000.0 in Q1 2026.
• The 4-year median for Cash from Operations is 24740000.0 (2025), against an average of 22712900.0.
• The widest annual swing landed in 2024, when Cash from Operations tumbled 273.72%; it then grew 20.46% in 2025.
• A 4-year view of Cash from Operations shows it stood at 8036000.0 in 2023, then sank by 273.72% to 30032000.0 in 2024, then climbed by 20.46% to 23886000.0 in 2025, then plunged by 57.03% to 37508000.0 in 2026.
• The last three Cash from Operations figures came in at 37508000.0 (Q1 2026), 23886000.0 (Q4 2025), and 29248000.0 (Q3 2025), per Business Quant data.

Peer Comparison